MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412638 | Name: Brofaromine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Brofaromine is a short-acting specific type A monoamine oxidase inhibitor.

Chemical Structure

Brofaromine
Brofaromine
CAS#63638-91-5

Theoretical Analysis

MedKoo Cat#: 412638

Name: Brofaromine

CAS#: 63638-91-5

Chemical Formula: C14H16BrNO2

Exact Mass: 309.0364

Molecular Weight: 310.19

Elemental Analysis: C, 54.21; H, 5.20; Br, 25.76; N, 4.52; O, 10.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
63638-90-4 (HCl) 63638-91-5 (free base)
Synonym
Brofaromine; CGP11305; CGP-11305; CGP 11305
IUPAC/Chemical Name
4-(7-Bromo-5-methoxy-2-benzofuranyl)piperidine
InChi Key
WZXHSWVDAYOFPE-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H16BrNO2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16H,2-5H2,1H3
SMILES Code
COC1=CC(Br)=C(OC(C2CCNCC2)=C3)C3=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 310.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Waldmeier PC. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine. Prog Neuropsychopharmacol Biol Psychiatry. 1993 Mar;17(2):183-98. doi: 10.1016/0278-5846(93)90042-q. PMID: 8430214. 2: Volz HP, Gleiter CH, Waldmeier PC, Struck M, Möller HJ. Brofaromine--a review of its pharmacological properties and therapeutic use. J Neural Transm (Vienna). 1996;103(1-2):217-45. doi: 10.1007/BF01292628. PMID: 9026374. 3: Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl. 1989;28:5-20. PMID: 2677242. 4: Waldmeier PC, Glatt A, Jaekel J, Bittiger H. Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor. Clin Neuropharmacol. 1993;16 Suppl 2:S19-24. PMID: 8313393. 5: Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC. Brofaromine for social phobia: a multicenter, placebo-controlled, double- blind study. J Clin Psychopharmacol. 1997 Aug;17(4):255-60. doi: 10.1097/00004714-199708000-00003. PMID: 9241003. 6: Möller HJ, Volz HP. Brofaromine in elderly major depressed patients--a comparative trial versus imipramine. Eur Neuropsychopharmacol. 1993 Dec;3(4):501-10. doi: 10.1016/0924-977x(93)90275-q. PMID: 8111223. 7: Bieck PR, Firkusny L, Schick C, Antonin KH, Nilsson E, Schulz R, Schwenk M, Wollmann H. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther. 1989 Mar;45(3):260-9. doi: 10.1038/clpt.1989.26. PMID: 2920501. 8: Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA, et al. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clin Neuropharmacol. 1993;16 Suppl 2:S51-4. PMID: 8313397. 9: Möller HJ, Volz HP. Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year. J Affect Disord. 1992 Nov;26(3):163-72. doi: 10.1016/0165-0327(92)90012-u. PMID: 1460166. 10: Feifel N, Kucher K, Fuchs L, Jedrychowski M, Schmidt E, Antonin KH, Bieck PR, Gleiter CH. Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor. Eur J Clin Pharmacol. 1993;45(3):265-9. doi: 10.1007/BF00315394. PMID: 8276052.